Adicet Bio, Inc. (ACET)
NASDAQ: ACET · Real-Time Price · USD
7.13
-0.12 (-1.66%)
At close: Feb 10, 2026, 4:00 PM EST
7.02
-0.11 (-1.54%)
After-hours: Feb 10, 2026, 7:52 PM EST
Adicet Bio Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
152
Market Cap
72.06M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | 24.99M | 15.26M | 156.83% |
| Dec 31, 2021 | 9.73M | -8.17M | -45.65% |
| Dec 31, 2020 | 17.90M | 16.91M | 1,699.30% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| MindWalk Holdings | 19.02M |
| Pelthos Therapeutics | 7.41M |
| ImageneBio | 800.00K |
| Coeptis Therapeutics Holdings | 501.00K |
| iBio, Inc. | 500.00K |
| Fractyl Health | 3.00K |
ACET News
- 11 days ago - Adicet Bio to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026 - Business Wire
- 4 weeks ago - Adicet Bio Provides Corporate Update and Highlights Expected 2026 Milestones - Business Wire
- 6 weeks ago - Adicet Bio Announces Reverse Stock Split - Business Wire
- 2 months ago - Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Adicet Bio Reports Third Quarter 2025 Financial Results and Provides Business Updates - Business Wire
- 3 months ago - Adicet Bio Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 3 months ago - Adicet Bio to Participate in a Fireside Chat at the Guggenheim 2nd Annual Healthcare Innovation Conference - Business Wire
- 4 months ago - Adicet Bio Announces First Patient Dosed in Phase 1 Clinical Trial of ADI-001 in Treatment-Refractory Rheumatoid Arthritis (RA) - Business Wire